The purpose of this study was to determine the safety, tolerability and pharmacokinetics of ascending single oral doses of JTK-853 administered under fasted or fed conditions in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
70
Tablets, single dose, fasted, fed or high-fat fed condition
PPD, Phase I Clinic
Austin, Texas, United States
Number of subjects with adverse events
Time frame: 1 week
Maximum concentration (Cmax) of JTK-853 and metabolite M2
Time frame: 1 week
Time to reach peak or maximum concentration following drug administration (tmax) for JTK-853 and metabolite M2
Time frame: 1 week
Area under the concentration-time curve from the time of dosing to the last quantifiable time point (AUClast) for JTK-853 and metabolite M2
Time frame: 1 week
Area under the concentration-time curve from the time of dosing to infinity (AUCinf) for JTK-853 and metabolite M2
Time frame: 1 week
Elimination half-life associated with the terminal slope (λz) of a semilogarithmic concentration-time curve (t1/2) for JTK-853 and metabolite M2
Time frame: 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.